Metabolic characterization of the natural progression of chronic hepatitis B

Leiden Repository

Metabolic characterization of the natural progression of chronic hepatitis B

Type: Article / Letter to editor
Title: Metabolic characterization of the natural progression of chronic hepatitis B
Author: Schoeman, J.C.Hou, J.Harms, A.C.Vreeken, R.J.Berger, R.Hankemeier, T.Boonstra, A.
Journal Title: Genome medicine
Issue: 1
Volume: 8
Start Page: 64
Issue Date: 2016
Abstract: BACKGROUND Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, emphasizes the interlinked nature of host metabolism and the disease. Still, the metabolic processes operational during the distinct clinical phases of a chronic HBV infection-immune tolerant, immune active, inactive carrier, and HBeAg-negative hepatitis phases-remains unexplored. METHODS To investigate this, we conducted a targeted metabolomics approach on serum to determine the metabolic progression over the clinical phases of chronic HBV infection, using patient samples grouped based on their HBV DNA, alanine aminotransferase, and HBeAg serum levels. RESULTS Our data illustrate the strength of metabolomics to provide insight into the metabolic dysregulation experienced during chronic HBV. The immune tolerant phase is characterized by the speculated viral hijacking of the glycerol-3-phosphate-NADH shuttle, explaining the reduced glycerophospholipid and increased plasmalogen species, indicating a strong link to HBV replication. The persisting impairment of the choline glycerophospholipids, even during the inactive carrier phase with minimal HBV activity, alludes to possible metabolic imprinting effects. The progression of chronic HBV is associated with increased concentrations of very long chain triglycerides together with citrulline and ornithine, reflective of a dysregulated urea cycle peaking in the HBV envelope antigen-negative phase. CONCLUSIONS The work presented here will aid in future studies to (i) validate and understand the implication of these metabolic changes using a thorough systems biology approach, (ii) monitor and predict disease severity, as well as (iii) determine the therapeutic value of the glycerol-3-phosphate-NADH shuttle.

Files in this item

Description Size View
application/pdf GenomeMedicine8(2016)64.pdf 1.707Mb View/Open Full text at publisher site

This item appears in the following Collection(s)